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Introduction
Viruses are extreme obligate parasites that are strictly 
dependent on the host’s energy and biosynthetic pathways 
for their replication and morphogenesis, and therefore, these 
pathways, in particular, afford the host critical immune and 
non-immune checkpoints to control infection [1]. Notably, 
the homeostatic regulation of these pathways not only acts 
to maintain a dynamic equilibrium but also plays a vital role 
in responding to a wide range of external stimuli, such as 
infection, which at a systems level must integrate and coor-
dinate multiple diverse processes ranging from the homeo-
stasis of membranes to energy and immunity [2–4]. Using 
this line of reasoning, we previously put forward the con-
cept for the ‘homeostatic regulation of infection’ which is 
highly relevant to a wide range of pathogens including cyto-
megalovirus (CMV) and other members of the herpes virus 
family that are clinically important and well known to estab-
lish lifelong infections [3]. Homeostasis therefore underpins 
many of the regulatory principles discussed in this review.
Historically, the immune system and metabolism have 
been intensively investigated at different times and by sepa-
rated research communities (immunologist and biochem-
ists) leading to an unintended misperception that these act 
as independent systems. However, there is now increasing 
evidence to show that these two systems are intimately 
integrated, share resources and cross-regulate each other 
[5–10]. While we will highlight some of these recent stud-
ies in relation to cytomegalovirus infection, we refer read-
ers to a number of excellent recent reviews that cover the 
elucidation of the molecular mechanisms linking some of 
these systems [6–10]. At the cellular level, viral infection 
adds considerable burden to the cell with the increased 
demand for energy and metabolic building blocks that are 
commandeered for the production of new viral progeny. A 
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number of different viruses have been demonstrated to alter 
the metabolism of infected cells, including, but not limited 
to hepatitis C virus, rift valley virus, human immunodefi-
ciency virus and human CMV (HCMV) [11–14]. These 
changes may be pro, or antiviral, or simply bystander 
effects. In the case of cytomegalovirus infection of mac-
rophages, some of these metabolic alterations, in particular 
lipid biosynthesis, have been mechanistically linked to the 
interferon (IFN) response [15, 16].
Here, we provide a discussion of how cytomegalovi-
rus infection modifies metabolism of the host cell, how 
immune signalling regulates metabolism and how interme-
diate metabolites can regulate all three processes: infection, 
the immune response to infection and metabolism itself. 
Finally, as a perspective for grappling with this new and 
emerging understanding, we place metabolism at the cen-
tre of an immune–metabolic–infection axis that integrates 
signals from both the host and pathogen. We propose that 
metabolism provides a highly tunable switch used by both 
viruses and the immune system to regulate infection. Hence, 
the lessons learnt from how the immune system regulates 
metabolism will inform new therapeutic strategies targeting 
metabolic enzymes to control acute and latent infections.
Sugar requirement and immune regulation
In normal resting cells, glucose provides the main car-
bon energy source and is actively imported into cells and 
rapidly converted to pyruvate in order to enter the tricar-
boxylic acid cycle (TCA), where it is catabolised to CO2 
through oxidative phosphorylation and which leads to the 
production of ATP [17, 18]. These processes of using glu-
cose require oxygen. However, under anaerobic conditions, 
cells can switch to a more inefficient way of using glucose 
that converts it to lactate. This leads to a smaller number of 
ATP production per glucose molecule (two ATP molecules) 
in comparison with oxidative phosphorylation (36 ATP 
molecules) [19]. Importantly, this now allows the sugar car-
bons to be used as building blocks for anabolic processes 
rather than eliminating through the generation of CO2.
Indeed, it was Otto Warburg in 1924 that made the key 
fundamental observation that cancer cells, despite the fact 
that they have adequate supply of oxygen, utilise anaerobic 
metabolism [20]. He posited that in order for a cell to divide 
it needs to increase its biomass by reprogramming the TCA 
cycle for anabolic purposes [21, 22]. In this scenario, pyru-
vate (a product of the glycolytic pathway) in the TCA cycle 
can get converted to citrate that can be shuttled to the cyto-
sol instead of completing the whole TCA cycle (Fig. 1). 
There it can be converted to acetyl-CoA and be used for 
the biosynthesis of fatty acids which could be employed to 
form cell organelles and support division. In fact, a number 
of studies have shown that as cancer progresses, there is an 
increased production in fatty acid biosynthesis [23]. A simi-
lar process in reprogramming the TCA cycle also occurs 
during immune stimulation and upon infection of cells.
Glycolytic and glutaminolysis pathways
Virus infection
A series of systematic metabolomics studies documented 
that infection of fibroblasts with HCMV dramatically 
alters the cell metabolome towards fatty acid biosynthe-
sis [14, 24, 25]. A comparison of Figs. 1 and 2 will aid in 
following the discussion of the changes that occur upon 
infection. Studies investigating the flux of 13C labelling in 
infected fibroblasts revealed that during infection, uptake 
of glucose is greatly enhanced and through increased gly-
colytic activity, carbon atoms are shuttled from glucose 
to citrate and then to fatty acid biosynthesis [14, 25, 26]. 
There are multiple regulatory steps involved in this process: 
according to McArdle and co-workers, HCMV activates 
AMP-activated protein kinase (AMPK), an energy sensor 
responding to low ATP/ADP ratios in cells, which in turn 
up-regulates glycolysis [27]; PKR-like endoplasmic reticu-
lum kinase (PERK), an ER-associated stress sensor protein 
[28] is induced; the sterol regulatory protein 1 (SREBP-1), 
a transcription factor for regulating fatty acid biosynthesis 
is up-regulated at late times of infection [29]; and expres-
sion of Glut-4, a glucose transporter (GLUT), and carbo-
hydrate-response element-binding protein (ChREBP), a 
transcriptional factor that regulates glucose metabolism 
and lipogenesis [30, 31] are induced during HCMV infec-
tion. All these alterations lead collectively to higher glu-
cose uptake and increased lipogenesis [29–31]. Along with 
changes in glycolysis, the virus also increases glutaminol-
ysis, and glutamine gets converted to α-ketoglutarate and 
through anaplerosis allows the TCA cycle to function [32]. 
Thus, while in normal diploid fibroblasts glutaminolysis is 
not required, it is essential for infected cells, and blockade 
of glutaminolysis significantly impacts on the viability of 
HCMV-infected cells [32]. Finally, Seo and Creswell [33] 
suggest that this cascade may also be regulated by viperin. 
Viperin is an IFN-stimulated multifunctional antiviral pro-
tein that gets hijacked by viral mitochondrial inhibitor of 
apoptosis (vMIA), a HCMV protein, resulting in altera-
tion of its function [33–35]. HCMV appears to up-regulate 
these pathways and inhibition of them and/or of fatty acids 
synthesis leads to reduction in viral progeny [11, 25, 36]. In 
fact, the concept of inhibiting metabolic pathways to block 
CMV infection it is not so new. As early as 1981, 2-deoxy-
d-glucose (2-DG), a glycolysis inhibitor, was shown to 
potently inhibit viral replication [37]. A schematic of these 
alterations is shown in Fig. 2.
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Immune activation
The question arises as to whether these changes upon infec-
tion are in isolation of immune activation. A comparison 
of Fig. 3 with 1 will aid in following the discussion of the 
changes that occur upon immune activation. In this regard, 
it is now emerging that immune cell activation also leads 
to marked detectable metabolic changes in cells [38]. Upon 
activation, lymphocytes, macrophages and dendritic cells 
have all been shown to alter dynamically their metabolism 
[39–42]. The precise metabolic changes that occur differ 
not only from cell type to cell type, but also between differ-
ent phenotypes of the same cell type [43]. For the purpose 
of this review, we will focus on discussing macrophages 
and dendritic cells (DCs) that are permissive to CMV and 
play a key role in viral dissemination and latency. A sche-
matic summary of these changes is shown in Fig. 3.
Immune-activated dendritic cells and macrophages show 
enhanced glycolysis and are further compromised in their 
ability to sustain oxidative phosphorylation in the presence 
of immune-activated nitric oxide (NO) production, as this 
molecule potently inhibits oxidative phosphorylation in the 
mitochondria [44]. Furthermore, in the case of immune-
activated macrophages, the reduced mitochondrial respira-
tion is also highly effective at augmenting the generation 
of anti-infective reactive oxygen species (ROS) [45]. In the 
case of resting DCs, oxidative phosphorylation is mainly 
used for energy purposes. However, when treated with Toll-
like receptor agonists, these cells adopt a Warburg style 
metabolism and after 12 h of activation, mitochondrial oxy-
gen consumption ceases and glucose uptake is increased 
even though it is not using the TCA cycle for ATP produc-
tion [44, 46]. As described above, this change allows DCs 
to survive the production of NO and when DCs are treated 
with 2DG at early stages of activation (before 6 h), the 
development of the activated phenotype is inhibited [44, 
46]. More recent studies reveal that this Toll-like receptors 
(TLR) activation supports anabolic demands of DCs which 
include biosynthesis of fatty acids through the shuttling of 
carbon atoms from glucose to TCA cycle and then de novo 
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Fig. 1  Metabolism of a resting uninfected cell. In a resting cell, glu-
cose is actively imported and used to fuel oxidative phosphorylation. 
The glycolytic pathway in the cytosol converts glucose to pyruvate. 
Pyruvate is imported into the mitochondria where it is used to gen-
erate NADH and FADH through the TCA cycle. NADH and FADH 
can be oxidised by the electron transport chain to generate ATP. Cit-
rate generated in the mitochondria can be shuttled out to generate 
cholesterol and fatty acids when this is required. Repression arrows 
indicate specific drug inhibitors. Glucose-6-P can also be shuttled to 
the pentose phosphate pathway where it can be used for generation 
of NADPH, nucleotides and purines. GLUT glucose transporter, TCA 
cycle tricarboxylic acid cycle
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synthesis of fatty acids and prostaglandins [47]. Similarly, 
IFN-activated macrophages are highly glycolytic and also 
adopt a Warburg style metabolism [42]. Much like DCs, 
macrophages shuttle glucose carbon to fatty acids and 
lipids synthesis, and at the same time, their pentose phos-
phate pathway (PPP) flux is increased [42]. These changes 
are required for meeting the demands for enhanced produc-
tion of membranes in the ER and golgi to accommodate the 
stimulated protein production as part of the immune-acti-
vated functions, including proteins for antigen presentation 
and cytokine production.
A critical part of this metabolic reprogramming is the 
very rapid (within minutes) accumulation and secretion of 
succinate, a metabolic intermediate of the TCA cycle, that 
has been shown to act as a signalling molecule for the acti-
vation of the alpha subunit of hypoxia-inducible factor-1 
(HIF-1a) and the induction of HIF-1a-dependent genes 
[48, 49]. A further interesting aspect of the crosstalk that 
occurs between metabolism and immunity is the availabil-
ity of substrates that may also alter the phenotype of mac-
rophages. For instance, overexpression of GLUT-1 leads to 
increases in glycolytic flux that drives a pro-inflammatory 
M1-like phenotype by macrophages without any other sig-
nalling [50].
Altogether, broadly comparing the isolated infec-
tion and immune activation studies, it appears that the 
alterations in energy and central carbon metabolism show 
metabolic cooperation, despite different cell type-based 
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Fig. 2  Metabolism of a cell infected by HCMV. A cell infected by 
HCMV has its metabolism heavily modified. Glucose importation 
is up-regulated due to up-regulation in the expression of GLUT-4. 
Glucose imported is converted to pyruvate, which can be oxidised 
to lactate for the generation of two molecules of ATP. Some of the 
pyruvate can be imported in the mitochondria and converted to cit-
rate and instead of being used in the TCA is rapidly shuttled out 
where it is employed for fatty acid biosynthesis. Glutamine importa-
tion is required in order to support the TCA cycle through anaplero-
sis, which is vital to maintain the mitochondrial membrane potential. 
If the mitochondrial membrane potential is lost, cytochromes get 
released in the cytosol and caspases are activated leading to apop-
tosis. The arachidonic pathway is also up-regulated, and there is 
increased release of arachidonic acid from membranes by lipases, 
which COX-2 converts to PGH2 a precursor for prostanoids. Repres-
sion arrows indicate specific drug inhibitors. TLR Toll-like receptor, 
IFN interferon, GLUT glucose transporter, TCA cycle tricarboxylic 
acid cycle, HK-II hexokinase-II, Akt protein kinase B, NO nitric 
oxide, NSAIDS non-steroidal anti-inflammatory inhibitory drugs, 
PPP pentose phosphate pathway
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investigations. The apparent parallel trajectories of infected 
and immune-activated cells (compare Figs. 2, 3) strongly 
suggest that rather than the virus driving these changes, it 
has the option for co-opting at early times of infection the 
TLR-mediated signalling of metabolism. It will be impor-
tant in the future to determine whether CMV-infected mac-
rophages also exhibit a similar alteration in flux and meta-
bolic functions.
Lipogenic requirement and immune regulation
Lipids are a diverse family of chemically distinct molecules 
that can be hydrophobic or amphipathic and serve multiple 
roles in a cell. They are used to store energy, signal and 
maintain cellular structure and have a key building role for 
all membranes and organelles [51] including for the growth 
of viruses. For instance, an important class of non-steroidal 
lipids that act as signalling molecules in immunity are reti-
noids, which are also known to directly and indirectly con-
trol HCMV and MCMV gene expression and viral replica-
tion [52–54].
Figure 4 shows the results of very early experiments 
that we conducted to directly test a potential lipogenic 
requirement for CMV growth in cells. For these studies, 
fibroblasts were incubated in medium supplemented with 
charcoal-treated serum (delipidised media), in which bio-
logically active lipid factors had been removed, and were 
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Fig. 3  Metabolism of a macrophage activated by immune signals. 
Upon activation of TLRs, the cell releases downstream IFN and at the 
same time, TBK1-IKKε kinases are activated leading to iNOS, Akt 
and NF-KB activation. This leads to increased glycolysis through 
activation of HK-II. NO production is also up-regulated from iNOS 
and blocks generation of ATP by mitochondria, and this also leads in 
up-regulation of glycolysis in order to produce ATP from pyruvate 
fermentation. Part of the pyruvate produced by glycolysis is imported 
to mitochondria where it gets converted to citrate and shuttled to the 
cytosol and used for fatty acids synthesis required by the cell for 
its activation. At the same time due to direct signalling by IFN, the 
mevalonate–sterol pathway is down-regulated. In the arachidonic 
pathway, COX2 is activated by NF-KB and prostanoids produced by 
are used as signals in an autocrine and paracrine way to regulate the 
immune response. Repression arrows indicate specific drug inhibi-
tors. The key differences to note in comparison Fig. 2 are TLR acti-
vation alone involving HK-II activation by Akt and that TLR agonist 
is the activator and not virus. TLR Toll-like receptor, IFN interferon, 
GLUT glucose transporter, TCA cycle tricarboxylic acid cycle, HK-II 
hexokinase-II, Akt protein kinase B, NO nitric oxide, NSAIDS non-
steroidal anti-inflammatory inhibitory drugs, PPP pentose phosphate 
pathway
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subsequently infected with murine CMV (MCMV) and 
analysed for viral production. As shown in Fig. 4, the 
growth of CMV was statistically strongly attenuated under 
these lipid-depleted conditions. It is worth noting that cell 
viability was not significantly affected by the removal of 
lipids in the culture medium in the conditions of the assay. 
We next asked whether a pro-viral lipogenic component 
in the serum was possibly removed. To test this notion, a 
chloroform–methanol method for removing lipids was used 
[55] whereby neutral lipids (triglycerides, waxes and pig-
ments) are extracted by chloroform and phospholipids; 
glycoproteins and cholesterol are removed by methanol. 
These extracted lipids were subsequently used to reconsti-
tute the delipidised serum. Notably, we found that addition 
of the reconstituted lipids to the delipidised media sub-
stantially reversed the viral growth defect exhibited after 
lipid depletion (Fig. 4a). It is possible that the delipidised 
media conditions simply impacts the cell by reducing an 
essential ‘lipid’ resource for the production of viral mem-
branes, or alternatively but not mutually exclusive, is the 
possibility for a pro-viral regulatory lipogenic factor. In 
order to distinguish between these possibilities, we sought 
to test whether the capacity of infected cells to generate 
infectious particles under delipidised media conditions is 
due to limited membrane lipid resources. In order to assess 
the maximal capacity for additional virus production under 
delipidised culture conditions, we employed a well-estab-
lished and potent regulatory lipid for enhancing CMV, 
9-cis retinoic acid (RA) [54]. Treatment of cultures in deli-
pidised medium with 9-cis RA led to a notable increase 
in MCMV growth that reached levels comparable or even 
higher than those obtained in cultures containing the nor-
mal medium, indicating that resources are not limiting the 
capacity of the cell to produce virus (Fig. 4b). Thus, these 
investigations reveal a requirement of lipogenic factors for 
optimal MCMV infection and indicate that this dependency 
is not only due to a deficit of membrane resources for viral 
growth in the cells. Please note that we do not infer from 
these experiments that retinoic acid is the regulatory lim-
iting lipogenic component although this possibility cannot 
be excluded. Most importantly, these experiments under-
score that careful consideration should be given to inter-
preting experiments that block or deprive cells of lipids 
and assessing the impact on viral growth. For this reason, 
the view that a pro-viral host lipid represents a depleted 
resource may not necessarily be the case and should be dis-
tinguished from possible effector or regulatory signalling 
functions. In the next section, we discuss the functional 
roles and alterations that occur for lipids upon infection and 
immune activation.
Long chain fatty acid pathway
Virus infection
As described above, HCMV infection shuttles carbon 
atoms to fatty acid synthesis (compare Figs. 1, 2). Fatty 
acids are carboxylic acids with long aliphatic tails. Fatty 
acid synthesis begins in the cytosol with the conversion of 
acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase 
(ACACA), the committing step in fatty acid biosynthesis 
(Fig. 1). Fatty acid synthase (FASN) then uses malonyl-
CoA to add two more carbon atoms to the aliphatic chain 
of a fatty acid. Fatty acids are elongated up to 16 carbons 
from FAS, and then, they can be elongated further in the 
ER by the elongation system in which fatty acid elongases 
(ELOVLs) play a vital role [56] (Fig. 1).
Drug inhibition of ACC with TOFA and of FASN with 
C-75 or other inhibitors have shown marked inhibition of 
HCMV replication [25, 36]. HCMV has also been shown to 
up-regulate ACC expression along with a number of other 
enzymes important for fatty acid biosynthesis. More recent 
studies have demonstrated that the virus requires very long 
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Fig. 4  Lipogenic factor requirement for MCMV growth. a NIH 
3T3 cells are pre-treated with normal (DMEM 3 % CS), delipidised 
(DMEM 3 % charcoal resin-treated CS) or reconstituted (DMEM 3 % 
charcoal resin-treated CS containing chloroform–methanol serum 
extracted lipids) medium for 4 h and then infected with MCMV at a 
multiplicity of infection (MOI) of 0.02. After infection, cells received 
the corresponding medium (normal, delipidised or reconstituted). 
Viral titers are determined by plaque assay at day 7 after infection 
from culture supernatants. n = 4, data are mean ± SD. b NIH 3T3 
cells are pre-treated with normal, delipidised or 10 μM 9-cis RA in 
delipidised medium for 4 h and then infected with MCMV at an MOI 
of 0.01. After infection, cells received the corresponding medium 
(normal, delipidised without or with 10−9 M 9-cis RA. Viral titres 
are determined as in a. n = 3, data are mean ± SD. **p ≤ 0.01; 
***p ≤ 0.001, determined with an unpaired Student’s t test
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chain fatty acids (VLCFAs) to replicate effectively [11]. 
Inhibition of specific ELOVLs attenuated the replication 
of the virus, and the fact that the envelope of the virus in 
untreated fibroblasts was strikingly enriched for those spe-
cific fatty acids, suggesting that indeed the requirement for 
this pathway may act at the viral membrane level. In fur-
ther support of this, it was also noted that inhibition of the 
pro-viral ELOVLs does not significantly reduce the num-
ber of virions, but instead greatly reduces infectivity. This 
was attributed to the ability of those VLCFAs to produce an 
envelope with correct curvature or other physicochemical 
properties necessary to bud virions from cells [11]. In this 
connection, phospholipids are essential membrane struc-
tural lipids consisting of a hydrophobic fatty acid tail. For 
HCMV, the glycerophospholipid composition of the virus 
membrane has been found to be very similar to synaptic 
vesicles suggesting a re-purposing or modelling of the host 
lipid membranes for its morphogenesis [57]. HCMV in 
general dramatically remodels the structure of a cell, lead-
ing to the gross enlargement of infected cells (cytomegalic) 
and the formation of a new compartment termed the virion 
assembly compartment (VAC) [58]. VAC is a kidney-
shaped structure adjacent to the nucleus that is crucial for 
HCMV replication and is formed by extensive remodelling 
of the secretory membrane apparatus [59–61].
Immune activation
The immune activation of cells also impacts on lipid and 
fatty acid metabolism [62–64], see Fig. 3 for a schematic 
summary of pathways. As described above, macrophages 
and DCs of specific phenotypes promote de novo fatty acid 
synthesis upon activation [47, 65]. Although still not well 
understood, these changes appear to be important for the 
activated function of the cell; for instance, inhibiting fatty 
acid synthesis can impair phagocytosis [65]. An activated 
macrophage leads to significant changes in phospholipids 
and fatty acids that promote the formation of filopodia and 
the biogenesis of new organelles such as mitochondria, 
lysosomal compartments, and expanded ER and golgi [47, 
65, 66]. These metabolic changes are therefore essential 
for activated macrophages and dendritic cells to be trans-
formed, from small quiescent cells to cells that are actively 
phagocytic, present antigens and secrete a huge number of 
cytokine and immune regulatory molecules.
Altogether, these immune-driven changes appear to 
have similarity to those observed in infected cells despite 
the studies being conducted in different cell types and 
point to a more unified response (compare Figs. 2, 3). This 
raises again the question of whether immune activation 
initiates the metabolic changes that upon infection also 
opportunistically favour viral growth. In this scenario, 
such immune-initiated re-programming of metabolism 
may be required and co-opted by the virus but alone may 
not be sufficient. Future studies should address whether it 
is likely that additional metabolic state changes are fur-
ther needed to encourage viral growth, and we speculate 
that viral gene products may have a contributory role in 
governing metabolic programming in the infected cell.
Prostanoid biosynthesis pathway
Virus infection
As mentioned at the start of the lipid section, not all lipids 
will necessarily have a structural role as membrane lipids 
but may also contribute regulatory functions or signals that 
promote or inhibit viral growth. In this regard, an interest-
ing class of signalling lipids that HCMV appears to depend 
on are eicosanoids. These are produced by oxidation of 
20 carbon fatty acids and play critical regulatory signal-
ling roles in immunity and inflammation. Upon infection 
of fibroblasts, HCMV up-regulates the expression of genes 
related to the eicosanoids pathway [67, 68]. Among them 
are cytosolic phospholipase A2 (cPLA2) and cyclooxyge-
nase-2 (COX-2) that are responsible for the generation of 
prostaglandin H2 (PGH2) acid from cell membranes and its 
conversion to prostaglandin H2 (PGH2) [69–71]. The inhi-
bition of COX-2 has been shown to reduce HCMV progeny 
while the introduction of prostaglandin E2 (PGE2) rescues 
the drug blockade [71]. While the antiviral mechanism for 
inhibition is not clear, PGE2 has been reported to stimulate 
the activity of the virus major immediate early promoter 
[72]. A later report from Schröer and Shenk [71] demon-
strated that inhibition of COX-2 also blocks cell-to-cell 
viral spread although the precise mechanism has not been 
defined.
In addition to the studies indicating that blocking pros-
taglandin synthesis inhibits viral growth, we have previ-
ously reported through evaluation of a highly selective and 
chemically diverse synthetic prostanoid library that the rep-
lication of MCMV can be enhanced or strongly curtailed 
depending on the specific prostanoid chemical structure 
[73]. Thus, altogether these studies suggest key regulatory 
functions for prostanoid signalling in determining the out-
come of a viral infection. In this context, we have been suc-
cessful, as a proof-of-principle study, to identify a potential 
therapeutic prostanoid that had potent anti-CMV activity 
[73].
Immune activation
The inflammatory induction of prostaglandins and other 
related lipids by macrophages and DCs have a critical sec-
ondary autocrine and paracrine signalling role in immunity 
[70, 74, 75]. Notably, lipidomic studies of the macrophages 
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have revealed that upon activation with a selective TLR4 
agonist, a rapid increase in eicosanoid synthesis takes place 
[76]. Depending on factors such as the nature of the signal-
ling or length of exposure to it, different outcomes on lipid 
alterations have been reported in macrophages and DCs 
[77, 78]. Moreover, differential gene regulation of enzymes 
that participate in the eicosanoid biosynthesis pathway 
has been documented in pro-inflammatory (M1) and anti-
inflammatory (M2) polarised macrophages [79]. Thus, IFN 
and LPS activation of M1 macrophages potently induced 
COX-2, and down-regulated COX-1 and other pathway-
related enzymes, such as leukotriene A4 hydrolase. In 
contrast, M2 macrophages activated with IL-4 exhib-
ited an up-regulation of COX-1. TLR treatment of mac-
rophages induced the microsomal isoform of PGE synthase 
(mPGES). On the other hand, Th2-associated cytokines 
IL-4 and IL-13 down-regulated the expression of mPGEs in 
macrophages [80].
In turn, prostanoids released from macrophages and 
DCs participate in autocrine loops to regulate COX-2 
expression. In macrophage cells, PGE2 has been reported 
to induce COX-2 and mPGES-1 [81]. In addition, released 
prostanoids are able to affect, either in a positive or in a 
negative manner, a number of macrophage and DC func-
tions [78]. As an example, PGE2 has been shown to usu-
ally exert inhibitory actions on macrophages and DCs, 
such as suppressing MHC class II expression and TNF-α 
production and inducing IL-10 expression [82–84]. How-
ever, PGE2 has also been documented to exert stimulatory 
effects on these two cell types, including the induction of 
IL-23 in DCs through cooperation of PGE2 with CD40-
mediated signalling [85]. Most significantly, PGE2 release 
from myeloid cells has been shown to restrain T cell activa-
tion, and clinical trials have revealed that blockade of PGE2 
synthesis exacerbates severe systemic inflammation. In this 
connection, it has also been suggested that PGE2 released 
from HCMV-infected macrophages may contribute to the 
immunosuppressive activity of HCMV [86]. Future studies 
elucidating the regulatory role of PGE2 in immunity will 
significantly advance our understanding of lipid host pro-
tection pathways modulated in cytomegalovirus disease.
Mevalonate–sterol pathway for cholesterol biosynthesis
Virus infection
Cholesterol is known to have a causal link to inflammatory 
diseases and its oxidised metabolites (oxysterols) alter adap-
tive and innate immunity, and innate immune signalling has 
been shown to modulate the dynamics of cholesterol homeo-
stasis [62–64, 87]. In this connection, over the last century, 
natural and experimental infection studies have reported for 
a wide range of pathogens a state of hypocholesterolemia 
during the acute phase (2–4 days) of infection that is often 
followed by a rebound period of hypercholesterolemia [88–
96]. Currently in the critical care of sepsis, monitoring of cho-
lesterol levels is used as a biomarker for prognosis. Although 
blood cholesterol levels for CMV infection have not been 
measured, acute hepatic infection by MCMV has been shown 
to increase total cholesterol levels in the liver [97]. Hence, the 
biosynthesis and metabolism of cholesterol takes centre stage 
in infection biology. Work from Alwine et al. [29] suggest 
that HCMV induces adipocyte-like lipogenesis and overrides 
normal sterol feedback controls in order to maintain high lev-
els of constitutive lipid synthesis during infection.
Cholesterol biosynthesis starts with acetyl-CoA whereby 
the reductase, HMGCR, represents a critical regulated step 
in the mevalonate arm of the sterol biosynthesis pathway 
(Fig. 1). The pathway is responsible not only for the pro-
duction of cholesterol but also for generating immune and 
sex steroid hormones while the upstream mevalonate arm 
of the pathway produces metabolites used in a diverse array 
of biological processes including the synthesis of ubiqui-
none for mitochondrial aerobic respiration with func-
tions in the electron transport chain, and other isoprenoids 
required for the N-gylcosylation and lipidation of proteins 
(farnesylation and geranylation of proteins). Thus, the inhi-
bition of HMGCR by statins not only reduces cholesterol 
but also has the ability to affect multiple products of the 
mevalonate side branch. Perhaps not surprisingly statins 
are potent inhibitors for human and murine CMV [15, 
98–100], and we were the first to show that the antiviral 
activity of statin on CMV can be metabolically reversed by 
mevalonate but not cholesterol treatment [15]. Recent stud-
ies have since independently confirmed the inhibition of 
HCMV by statins and metabolic rescue of antiviral action 
by using mevalonate [98]. The metabolic rescue experi-
ments unequivocally demonstrate the absolute requirement 
for mevalonate–sterol biosynthesis pathway for optimal 
CMV growth. In a series of systematic loss of function 
and drug inhibition assays, we have provided further evi-
dence implicating mevalonate-derived products such as 
isoprenoids involved in the lipidation of proteins for CMV 
growth [16, 101]. Inhibition of the mevalonate–sterol arm 
does not affect the binding or entry of CMV but evidence to 
date points to the suppression of the major immediate early 
gene expression as well as blocking cell-to-cell spread [16].
It is important to note that while these studies indicate 
that cholesterol alone is not the primary metabolite for sta-
tin antiviral action, they do not rule out an important bio-
logical requirement for cholesterol in the CMV life cycle. 
In this regard, studies evaluating the proteomes of fibro-
blasts cells before and after HCMV infection by mass spec-
troscopy identified LRP1, an LDL receptor-related protein 
involved in cholesterol uptake, as a transiently increased 
protein at 24 h after infection. In human fibroblasts, 
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knockdown of LRP1 was found to enhance HCMV infec-
tivity and also lead to increased cholesterol in released 
virions. Importantly, the cholesterol content of the virus 
envelope was shown to be critical for HCMV fusion with 
the host cell. These results indicate that increases in cel-
lular and virion cholesterol content lead to more efficient 
fusion of the virion envelope with the plasma membrane 
and therefore increased virion infectivity [102].
Upon infection of macrophages with MCMV, we found 
by metabolic and transcriptional profiling studies that one 
of the most statistically significant pathways suppressed 
upon infection was mevalonate–sterol metabolism. The 
reasons for this reduction are complex and may not be 
identical or equivalent in all cell types and media condi-
tions as this pathway is directly regulated by the immune 
response and by extracellular cholesterol. For instance 
in macrophages but not fibroblasts, we find a highly spe-
cific and dramatic increase in the production of an oxi-
dised cholesterol metabolite generated by the hydroxylase 
CH25H. The regulation of CH25H appears to be highly 
cell type and tissue specific and is mainly restricted to 
immune (myeloid and lymphoid) and to certain epithe-
lial cell types. We, and others, identified and showed that 
the metabolic product of CH25H enzyme, 25-hydroxy-
cholesterol (25HC), a well-characterised inhibitor of the 
mevalonate–sterol biosynthesis pathway, acts as a potent 
antiviral regulatory factor by principally suppressing the 
isoprenoid branch of the pathway and through affecting 
cellular membranes [16, 66, 103]. It remains an open 
question if CMV encodes viral proteins that counter these 
inhibitory effects. Previous studies from Alwine et al. 
[29] have suggested that HCMV infection of fibroblast 
can override normal sterol feedback control in order to 
maintain high levels of constitutive lipid synthesis during 
infection.
Overall, these studies underscore that the interplay 
between immune activation, infection and metabolic 
changes cannot be considered in isolation.
Immune activation
Similar to the early infection studies examining blood cho-
lesterol, in completely unrelated early investigational stud-
ies of recombinant IFN treatment in humans, for a range 
of different disease indications, a transient drop in blood 
cholesterol levels has also been repeatedly documented. 
Radiolabelled metabolic studies have further indicated 
that this particular side effect of IFN treatment is due to 
a suppression of endogenous sterol synthesis [94]. Strik-
ingly, mechanistic and functional physiological linkages 
between the observational based infection and IFN studies 
have not, until recently, been investigated or considered. 
IFN and TLR activation are now known to coordinate the 
reduction in cholesterol biosynthesis for human and murine 
macrophages [10, 15, 66, 76, 104]. We demonstrated that 
IFN-induced inhibition of sterol biosynthesis serves as an 
integral component of the very early cellular response to 
virus infection [15]. Metabolic profiling [15] and molecular 
screening [103] studies led ourselves and others to identify 
IFN-elicited 25HC as an important effector of the IFN-
induced antiviral response in macrophages [15, 16]. This 
lipid has emerged to have broad-spectrum antiviral and 
immune modulatory functions [10].
We demonstrated that CMV infection leads to a TLR-
induced type I IFN-mediated down-regulation of the mas-
ter transcription factor for sterol biosynthesis, SREBP2 
[15]. More recently, we have also shown that IFN signal-
ling specifically targets in a SREBP-independent manner 
the statin-targeted reductase, HMGCR, for rapid proteoso-
mal degradation that is strictly coupled to the endogenous 
synthesis of 25HC [105]. Our studies of immune-activated 
macrophages identified STAT1 transcriptional regulation 
of the cholesterol hydroxylase, CH25H, as a direct mech-
anistic link between IFN-mediated antiviral activity and 
the regulation of sterol metabolism [16]. Investigations 
of SREBP2-dependent IFN effects have implicated the 
sterol biosynthesis pathway involved in both antiviral and 
anti-inflammatory pathways [16, 106]. Further studies are 
required to more fully understand the role of SREBP2 and 
the mevalonate–sterol pathway in immunity and infection.
Therapeutic perspective
Here we have discussed how cytomegaloviruses are criti-
cally dependent on and co-opt many aspects of cellular 
sugar and lipid metabolism to facilitate their life cycles 
across species and how the inhibition of these processes 
can curtail virus replication. Overall, we find a remark-
able level of metabolic cooperation between infection and 
immunity. Defining how immunity and metabolism are 
integrated, share resources and cross-regulate one another 
during infection is therefore an essential yet incompletely 
understood area of infection biology. Notably, unbiased 
systems biology approaches are providing valuable new 
insights into this integrative complexity and computational 
studies based on predictive modelling will be essential in 
the future functional design and control of an immune–
metabolic–infection axis [107].
In this regard and to advance this future perspective, 
Fig. 5 summarises and shows as a schematic representa-
tion of the inputs and outputs for this axis, with metabo-
lism positioned in the middle connecting in an integrative 
manner the various distinct biological processes. Conceptu-
ally, this diagram extends our previous ‘cellular clockwork 
model of infection’ [1] that underscored the dependency of 
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pathogens on cellular pathways as a means for therapeutic 
drugs or the immune system to control infections. Here we 
extend the previous model to emphasise, at a systems con-
trol level, an important design principle suggesting that cel-
lular metabolism behaves as a ‘tunable device’ and that the 
control of metabolic flux in these pathways is necessary for 
driving the range and type of biological response (Fig. 5).
While the concept of metabolism acting as a ‘tunable 
device’ for governing cellular functions is new, it remains 
speculative yet testable for the future. Thus, we believe that 
further understanding and identifying the host molecular 
circuitry for new and recently discovered immune-regu-
lated metabolites and enzyme pathway systems will aid in 
the development of new therapeutic innovations to prevent 
infection (as an anti-infective) or enhance immunity (as 
adjuvant-based metabolic modifiers).
Although we have focussed our discussions on sugar 
and lipid pathways, these are not the only examples of an 
immune–metabolic–infection axis known to control infec-
tions. In particular, the immune-activated metabolism of 
amino acids has been long established. Stimulation of 
macrophages with IFN results in the rapid induction of the 
tryptophan-catabolising enzyme indoleamine-2,3-dioxyge-
nase resulting in broad-spectrum antimicrobial and immu-
nosuppressive effector functions. Other examples include 
the immune-regulated activities of the arginine-hydrolysing 
enzymes nitric oxide synthase 2 (iNOS) and arginase 1 
(Arg1). In the case of these enzyme systems, NO produc-
tion by iNOS acts as an important pro-inflammatory and 
antiviral mediator, while Arg1-expressing macrophages 
contribute to the resolution of inflammation and wound 
repair. In the context of viral infections, expression of 
these enzymes can result in a variety of outcomes for the 
host [108]. Interestingly, HCMV infection of fibroblast is 
capable of effectively impairing this response [109] and 
might suggest a similar mode of action for blocking the 
IFN-induced suppression of sterol biosynthesis.
Strikingly, the glycolytic and fatty acid metabolism 
changes that favour CMV growth in fibroblasts, parallels 
the metabolic profile of the pro-inflammatory immune-
activated macrophages, but not the anti-inflammatory 
macrophages. In future, it will be important to determine 
whether the metabolic cooperation in glycolytic and fatty 
acid pathways also occurs upon CMV infection of mac-
rophages. Since CMV remains latent in monocytes and 
reactivates upon immune activation and differentiation, 
it is plausible that CMV may also exploit these different 
metabolic stages of the macrophage phenotypes to remain 
latent and reactivate when conditions favour replication. If 
so, then therapeutic targeting (‘tuning’) of metabolism in 
latently infected monocytes may provide a means for cur-
ing or eliminating latently infected cells.
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